May 17 2010
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in the development of new preventive and therapeutic vaccines against cancers and infectious diseases, announced today that it has changed its corporate name to Inovio Pharmaceuticals, Inc. by filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware on May 14, 2010. Inovio's trading symbol remains the same.
“In the last year Inovio has made great strides in advancing its DNA vaccines for influenza, HIV and cancer and its proprietary vaccine delivery technology. The new name better reflects the company's product development leadership in unlocking the promise of DNA vaccines”
"In the last year Inovio has made great strides in advancing its DNA vaccines for influenza, HIV and cancer and its proprietary vaccine delivery technology. The new name better reflects the company's product development leadership in unlocking the promise of DNA vaccines," said Dr. J. Joseph Kim, President & CEO.
The CUSIP number for the company's common stock remains the same. Holders of stock certificates bearing the name "Inovio Biomedical Corporation" may continue to hold them and will not be required to exchange them for new certificates or take any other action.
SOURCE Inovio Pharmaceuticals, Inc.
Danish studies find increased risk of optic nerve damage with diabetes medicine